Key Details
Annual ROE
-24.38%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Mar 08, 2024Recent annual earnings:
Mar 08, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Screeners with THRX included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Similar stocks
Theseus Pharmaceuticals (THRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Theseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic alternatives to maximize shareholder value. The company cuts its workforce by 72%.
Theseus Pharmaceuticals experienced significant losses after discontinuing its lead program, leaving it with a market cap of half of its current assets. THRX is now focusing on developing a fourth-generation EGFR inhibitor for the treatment of EGFR-mutated non-small cell lung cancer. The company has enough funds to sustain operations until 2026, but the success of its pipeline drugs remains uncertain.
The heavy selling pressure might have exhausted for Theseus Pharmaceuticals, Inc. (THRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
The heavy selling pressure might have exhausted for Theseus Pharmaceuticals, Inc. (THRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Theseus (THRX) announces the discontinuation of enrollment in its phase I/II study of THE-630 in patients with gastrointestinal stromal tumors due to observed adverse reactions. The stock falls 72%.
Theseus Pharmaceuticals (NASDAQ: THRX ) stock is falling hard on Friday after the company announced poor results from a Phase 1/2 clinical trial. According to a press release from Theseus Pharmaceuticals, the company is no longer enrolling patients in its clinical trial for THE-630 in patients with gastrointestinal stromal tumors (GIST).
Theseus Pharmaceuticals Inc. THRX, -3.74% shares plummeted after hours Thursday after the biotech drug maker discontinued enrolling patients in the study of a cancer drug it no longer intend to develop. Theseus shares plunged as much as 75% in the extended session Thursday, following a 3.7% decline to close the regular session at $9.52.
The average of price targets set by Wall Street analysts indicates a potential upside of 128.8% in Theseus Pharmaceuticals, Inc. (THRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
FAQ
- What is the primary business of Theseus Pharmaceuticals?
- What is the ticker symbol for Theseus Pharmaceuticals?
- Does Theseus Pharmaceuticals pay dividends?
- What sector is Theseus Pharmaceuticals in?
- What industry is Theseus Pharmaceuticals in?
- What country is Theseus Pharmaceuticals based in?
- When did Theseus Pharmaceuticals go public?
- Is Theseus Pharmaceuticals in the S&P 500?
- Is Theseus Pharmaceuticals in the NASDAQ 100?
- Is Theseus Pharmaceuticals in the Dow Jones?
- When was Theseus Pharmaceuticals's last earnings report?
- When does Theseus Pharmaceuticals report earnings?
- Should I buy Theseus Pharmaceuticals stock now?